SOX2 expression has been reported to mark diverse ZIKV target cells including neural progenitor cells, oligodendrocyte precursor cells, astrocytes (Garcez et al., 2016; Retallack et al., 2016; Souza et al., 2016), and glioma stem cells(Chen et al., 2018; Zhu et al., 2017, 2020). Here, SOX2 is linked to central nervous system cancer.